JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

Interferon α (IFNα) is used to treat JAK2(V617F)-driven myeloproliferative neoplasms (MPNs) but rarely clears the disease. We investigated the IFNα mechanism of action focusing on PML, an interferon target and key senescence gene whose targeting by arsenic trioxide (ATO) drives eradication of acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagher, Tracy, Maslah, Nabih, Edmond, Valérie, Cassinat, Bruno, Vainchenker, William, Giraudier, Stéphane, Pasquier, Florence, Verger, Emmanuelle, Niwa-Kawakita, Michiko, Lallemand-Breitenbach, Valérie, Plo, Isabelle, Kiladjian, Jean-Jacques, Villeval, Jean-Luc, de Thé, Hugues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Brief Definitive Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579737/
https://www.ncbi.nlm.nih.gov/pubmed/33075130
http://dx.doi.org/10.1084/jem.20201268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579737/
https://www.ncbi.nlm.nih.gov/pubmed/33075130
http://dx.doi.org/10.1084/jem.20201268

Ejemplares similares